Why CGT biosimilars are categorically different: Manufacturing complexity: CAR-T cell therapy manufacturing is patient-specific (autologous) or donor-matched (allogeneic), involves live cell engineering, and produces a heterogeneous product whose sameness to a reference product cannot be defined the same way as a proteins amino acid sequence
Deeper bruises or those in areas with thinner skin may take slightly longer
The truth is that the overuse of any ingredient, especially Glutathione, may lead to redness, dryness or irritation
Some people may process these treatments more quickly or slowly, affecting how well they work
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Slower stomach emptying signals the brain to eat less, helping to manage weight
